Table 2 Summary statistics of decreases from baseline in cerebrospinal fluid Aβ 1–42 following administration of GSK933776 a
Sampling time (h) | GSK933776 (n = 6/dose) | Baselineb | Postdosing | Change (%) | 95% CI |
|---|---|---|---|---|---|
0 to 4 | 1 mg/kg | 363.4 ± 60.1 | 350.2 ± 61.7 | −3.6 | (−10.8 to 3.6) |
3 mg/kg | 479.2 ± 65.8 | 446.4 ± 70.8 | −6.8 | (−14.9 to 1.2) | |
6 mg/kg | 502.7 ± 71.1 | 456.1 ± 88.9 | −9.7 | (−15.4 to −3.9) | |
5 to 12 | 1 mg/kg | 363.4 ± 60.1 | 333.9 ± 52.1 | −7.9 | (−12.6 to −3.2) |
3 mg/kg | 479.2 ± 65.8 | 428.9 ± 77.1 | −10.7 | (−20.2 to −1.2) | |
6 mg/kg | 502.7 ± 71.1 | 433.5 ± 85.1 | −14.2 | (−19.8 to −8.6) | |
0 to 12 | 1 mg/kg | 363.4 ± 60.1 | 340.6 ± 55.7 | −6.2 | (−11.2 to −1.1) |
3 mg/kg | 479.2 ± 65.8 | 435.7 ± 74.4 | −9.2 | (−17.9 to −0.5) | |
6 mg/kg | 502.7 ± 71.1 | 442.2 ± 86.4 | −12.5 | (−18.0 to −7.0) |